Merck & Co. - Bathi saben saham sajrone 12 wulan pungkasan MRK

The prospects for Merck & Co., Inc. (MRK) depend on new developments in cardiology and oncology due to the upcoming patent expiration of Keytruda. The current EPS YoY TTM growth rate confirms the resilience of this trend, with the value stabilizing at -87.20. Gardasil vaccine sales and dividend payments provide stability. The monopoly status of the flagship drug guarantees premium pricing power despite regulatory pressure in the US.

MRK Merck & Co.: Bathi saben saham sajrone rolas wulan pungkasan ing interval 11.02.2024 - 14.11.2026

MRK (Merck Sharp & Dohme): rincian analitis lan laporan miturut indikator

- rega saham lan prakiraan rega para ahli:

Bagan rega merck.com|MRK - Prakiraan konsensus analis

- rincian nilai pasar emiten:

Kapitalisasi pasar Merck & Co., Inc.|MRK - Nilai Perusahaan

- indikator kapitalisasi buku:

Aset Bersih saben Saham Merck|MRK - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku merck.com|MRK - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

MRK - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Merck & Co., Inc.|MRK - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Merck & Co.|MRK - Rasio P/E diaturake wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Merck & Co., Inc.|MRK - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Merck|MRK - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan merck.com|MRK - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Merck & Co., Inc.

- rincian pendapatan lan dodolan:

MRK - Dodolan perusahaan|Dodolan mangsa ngarep perusahaan merck.com|MRK - Kapitalisasi marang pendapatan|Rega forward marang dodolan Merck & Co., Inc.

Pambiji fundamental perusahaan:MRK, merck.com

Amidst a fierce battle for oncology leadership and the risks of patent expiration, Merck & Co., Inc. (MRK) is compelled to constantly scale its profits. This metric measures the percentage change in net earnings per share over a rolling year, reflecting the efficiency of R&D expenditures. This allows investors to distinguish organic growth from temporary market fluctuations. By analyzing the annual EPS growth rate over the last 12 months, one can assess the sustainability of the company's capitalization.

Analisis pesaing